Patents by Inventor Nagaraj Govindappa

Nagaraj Govindappa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20210301296
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: June 4, 2021
    Publication date: September 30, 2021
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
  • Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins
    Patent number: 11060097
    Abstract: The present invention provides for a composition and a method for treating a subject afflicted with a cancer, wherein the composition comprises therapeutically effective amounts of: (a) an anti-Programmed Death-Ligand 1 (PD-L1) antibody and (b) a targeted/immunomodulatory fusion protein comprising at least one tumor targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 13, 2021
    Inventors: Nagaraj Govindappa, Sreesha P. Srinivasa, Usha Bughani, Reshmi Nair
  • CTLA4/PD1 targeted/immunomodulatory fusion proteins
    Patent number: 11028399
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: June 8, 2021
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20200399379
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Inventors: NAGARAJ GOVINDAPPA, MARIA MELINA SOARES, KEDERNATH SASTRY
  • Fusion immunomodulatory proteins and methods for making same
    Patent number: 10766963
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: September 8, 2020
    Inventors: Nagaraj Govindappa, Maria Melina Soares, Kedernath Sastry
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20190367929
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 5, 2019
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
  • Epidermal growth factor receptor targeted/immunomodulatory fusion proteins and methods of use for them
    Patent number: 10385348
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: August 20, 2019
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS IN COMBINATION WITH ADDITIONAL THERAPEUTIC AGENTS AND METHODS FOR MAKING SAME
    Publication number: 20190169621
    Abstract: The present invention provides for a composition and a method for treating a subject afflicted with a cancer, wherein the composition comprises therapeutically effective amounts of: (a) an anti-Programmed Death-Ligand 1 (PD-L1) antibody and (b) a targeted/immunomodulatory fusion protein comprising at least one tumor targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: January 31, 2019
    Publication date: June 6, 2019
    Inventors: NAGARAJ GOVINDAPPA, SREESHA P. SRINIVASA, USHA BUGHANI, RESHMI NAIR
  • Targeted/TGF-ßRII fusion proteins and methods for making same
    Patent number: 10144934
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: December 4, 2018
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20180251560
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Application
    Filed: May 1, 2018
    Publication date: September 6, 2018
    Inventors: NAGARAJ GOVINDAPPA, MARIA MELINA SOARES, KEDERNATH SASTRY
  • Fusion immunomodulatory proteins and methods for making same
    Patent number: 9988456
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: June 5, 2018
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Maria Melina Soares, Kedernath Sastry
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20180066057
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: October 27, 2017
    Publication date: March 8, 2018
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • Nucleotide sequence and a process thereof
    Patent number: 9862958
    Abstract: The present disclosure relates to a process of identification and isolation of sorbitol dehydrogenase promoter from Pichia pastoris. Further, the present disclosure also relates to expression of heterologous proteins under the control of Sorbitol dehydrogenase promoter in Pichia pastoris.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: January 9, 2018
    Assignee: Biocon Limited
    Inventors: Nagaraj Govindappa, Sankar Periyasamy, Shivakumar Madenahalli Channabasappa, Suma Sreenivas, Kedamath Nanjund Sastry
  • Method of treating cancer with an EGFR targeted immunomodulatory fusion protein
    Patent number: 9809651
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: November 7, 2017
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • Anti-CTLA4 antibody-TGF-?RII targeted/immunomodulatory fusion proteins
    Patent number: 9758582
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: September 12, 2017
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20170233747
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 17, 2017
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20160237155
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: May 3, 2016
    Publication date: August 18, 2016
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
  • Process of expressing a fully folded functional two chain insulin glargine
    Patent number: 9388227
    Abstract: The disclosure relates to a process of obtaining a fully folded two chain insulin glargine that require no further processing to make it functionally active. The present disclosure discloses a surprising effect of over expression of Kex2p intracellularly under the control of inducible FLD1 promoter in the host Pichia pastoris to produce two chain functional glargine secreted directly in the medium. The schematic diagram of how the two chains are made inside the host Pichia pastoris and secretes into the medium.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: July 12, 2016
    Assignee: Biocon Limited
    Inventors: Nagaraj Govindappa, Suma Sreenivas, Komal N. Kanojia, Yogesh Basavaraju, Kedamath Nanjund Sastry
  • SIGNAL SEQUENCE FOR PROTEIN EXPRESSION IN PICHIA PASTORIS
    Publication number: 20160168198
    Abstract: The present invention relates to a signal sequence from a unique Pichia pastoris protein. Further the invention discloses use of signal sequence for the expression of heterologous protein in Pichia pastoris.
    Type: Application
    Filed: June 27, 2014
    Publication date: June 16, 2016
    Inventors: Nagaraj Govindappa, Suma Sreenivas, Sankar Periyasamy, Srividya Divakar
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
    Publication number: 20160168260
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 16, 2016
    Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES